Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.45 |
| ▸ | BDKRB2 | P30411 | 2/20 | 0.44 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.43 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rotigaptide SCHEMBL29359046 | 1.00 | VHL (0.49) | VHLOPRD1OPRM1BDKRB2NMUR2 | |
| Rotigaptide SCHEMBL20547994 | 1.00 | VHL (0.49) | VHLOPRD1OPRM1BDKRB2NMUR2 | |
| SCHEMBL19381802 | 0.94 | VHL (0.47) | VHLOPRD1OPRM1BDKRB2 | |
| SCHEMBL16925996 | 0.94 | VHL (0.47) | VHLOPRD1OPRM1BDKRB2 | |
| SCHEMBL20626228 | 0.93 | VHL (0.52) | VHLOPRD1OPRM1BDKRB2NMUR2 | |
| SCHEMBL31327461 | 0.86 | VHL (0.54) | VHLOPRD1OPRM1BDKRB2 | |
| SCHEMBL20782464 | 0.80 | F2 (0.37) | VHLOPRD1OPRM1 | |
| SCHEMBL10624291 | 0.79 | VHL (0.42) | VHLOPRD1BDKRB2 | |
| SCHEMBL19381804 | 0.78 | VHL (0.51) | VHLOPRD1OPRM1 | |
| SCHEMBL16925966 | 0.77 | VHL (0.52) | VHLOPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230123615-A1 | METHODS OF TREATMENT AND NOVEL CONSTRUCTS | INFLAMMX THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-11466069-B2 | Methods of treatment and novel constructs | AUCKLAND UNISERVICES LIMITED (NZ) | 2022-10-11 | — | — | US | disclosed |
| US-20210107963-A1 | METHODS OF TREATMENT AND NOVEL CONSTRUCTS | INFLAMMX THERAPEUTICS, INC. | 2021-04-15 | — | — | US | disclosed |
| US-20200354404-A1 | PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2020-11-12 | — | — | US | disclosed |
| WO-2020227588-A1 | PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2020-11-12 | — | — | WO | disclosed |
| CN-111201247-A | Therapeutic methods and novel constructs | 奥克兰联合服务有限公司 | 2020-05-26 | — | — | CN | disclosed |
| EP-3615575-A1 | METHODS OF TREATMENT AND NOVEL CONSTRUCTS | Auckland Uniservices Limited (NZ) | 2020-03-04 | — | — | EP | disclosed |
| WO-2018199777-A1 | METHODS OF TREATMENT AND NOVEL CONSTRUCTS | AUCKLAND UNISERVICES LIMITED (NZ) | 2018-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354404-A1 | PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF | DNPEP, PEPD, ANPEP | VHL 48/4885OPRD1 3982/4885OPRM1 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.